Adage Capital Partners
ALXO icon

Adage Capital Partners’s ALX Oncology ALXO Stock Holding History

Adage Capital Partners’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.01M Buy
+2,000,000
New +$3.81M 0.01% 792
2024
Q2 		– Sell
-160,000
Closed -$1.78M – 867
2024
Q1 		$1.78M Hold
160,000
– – ﹤0.01% 776
2023
Q4 		$2.38M Buy
+160,000
New +$1.52M ﹤0.01% 735

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Adage Capital Partners's ALXO Position: Q1 2026 in Review

Adage Capital Partners opened a new position in ALX Oncology (ALXO) in Q1 2026: 2,000,000 shares worth $4.01M. The stake represents 0.01% of the portfolio and ranks #792 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in ALXO as recently as Q1 2024.

Adage Capital Partners first reported a position in ALXO in Q4 2023 and has held it in 3 quarters since. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Adage Capital Partners held 2,000,000 shares of ALX Oncology worth $4.01M as of Q1 2026.
  • ALX Oncology was a new Adage Capital Partners position in Q1 2026.
  • ALX Oncology made up 0.01% of Adage Capital Partners's portfolio in Q1 2026, its #792 holding.
  • Adage Capital Partners first reported a position in ALX Oncology in Q4 2023 and has held it in 3 quarters since.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.